Kiniksa Pharmaceuticals International, plc (KNSA) P/E Ratio History
Fairly ValuedTrading at 101.1x, near 5Y avg of 113.5x · 82th percentile · In line with own history · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a price-to-earnings ratio of 101.1x, with a stock price of $75.79 and trailing twelve-month earnings per share of $0.97.
The current P/E is 11% below its 5-year average of 113.5x. Over the past five years, KNSA's P/E has ranged from a low of 3.9x to a high of 691.8x, placing the current valuation at the 82th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, KNSA trades at a 336% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, KNSA commands a significant premium over the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KNSA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KNSA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
KNSA P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.2Lowest | 0.60Best | +817%Best | |
| $43B | 32.9 | 0.81 | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
KNSA Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $63.95 | $0.98 | 65.3x | -43% |
| FY2026 Q1 | - | $48.15 | $0.91 | 52.9x | -53% |
| FY2025 Q4 | Dec 31 2025 | $41.25 | $0.75 | 55.0x | -52% |
| FY2025 Q3 | - | $38.83 | $0.45 | 86.3x | -24% |
| FY2025 Q2 | Jun 30 2025 | $27.67 | $0.04 | 691.8x | +510% |
| FY2024 Q1 | Mar 31 2024 | $19.73 | $0.11 | 179.4x | +58% |
| FY2023 Q4 | Dec 31 2023 | $17.54 | $0.18 | 97.4x | -14% |
| FY2023 Q2 | Jun 30 2023 | $14.08 | $3.27 | 4.3x | -96% |
| FY2023 Q1 | Mar 31 2023 | $10.76 | $2.77 | 3.9x | -97% |
| FY2022 Q4 | Dec 31 2022 | $14.98 | $2.59 | 5.8x | -95% |
| FY2022 Q3 | Sep 30 2022 | $12.84 | $2.00 | 6.4x | -94% |
Average P/E for displayed period: 113.5x
KNSA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KNSA — Frequently Asked Questions
Quick answers to the most common questions about buying KNSA stock.
What is KNSA's P/E ratio?
Kiniksa Pharmaceuticals International, plc (KNSA) trailing twelve-month P/E ratio is 101.1x, based on TTM diluted EPS of $0.97. The 5-year average P/E is 113.5x and the historical range spans 3.9x to 691.8x.
Is KNSA stock overvalued or undervalued?
KNSA trades at 101.1x P/E, near its 5-year average of 113.5x. The 82th percentile ranking within the 3.9x–691.8x historical range places valuation within normal bounds.
Is KNSA stock expensive?
KNSA is fairly valued relative to its own history. The current P/E of 101.1x is near the 5-year average of 113.5x (82th percentile of historical range).
What is KNSA's historical P/E range?
Over the past 5 years, KNSA's P/E ratio has ranged from 3.9x to 691.8x, with a median of 55.0x and an average of 113.5x. The current P/E of 101.1x places the stock at the 82th percentile of this range. Full historical data spans 2022–2026.
How does KNSA's P/E compare to the S&P 500?
KNSA trades at 101.1x P/E versus the S&P 500 median of 24.5x. The 313% premium to the market typically reflects higher expected earnings growth or quality.
How does KNSA's valuation compare to Healthcare peers?
Kiniksa Pharmaceuticals International, plc P/E of 101.1x compares to the Healthcare sector median of 23.2x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is KNSA's PEG ratio?
KNSA PEG ratio is N/A, based on a P/E of 101.1x and EPS growth of 225.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is KNSA's earnings yield?
KNSA earnings yield is 0.99%, the inverse of its 101.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.